Novel Antioxidant Can Provide a Number of Health Benefits for Peripheral Artery Disease According to 11 Patient Published Study

November 20, 2020

Novel antioxidant can provide a number of health benefits for individuals with peripheral artery disease according to researchers at the School of Health and Kinesiology at the University of Nebraska at Omaha.

Novel antioxidant specifically targets mitochondria, considered the powerhouse of the cell. The study was led by Assistant Professor Song-Young Park, Ph.D., and published in the American Journal of Physiology-Heart and Circulatory Physiology.

Park recruited eleven men and women with PAD to participate in this research; six of which received 80 milligrams of the antioxidant while the remaining five participants were given a placebo. Measurements were done before and 40 minutes after each participant took the supplement or placebo to assess the roles of vascular mitochondria in endothelial function, arterial stiffness, exercise tolerance, and skeletal muscle function. After a 14 day “wash out” period, the two groups switched, with the placebo group taking the supplement and vice versa, and measurements were assessed again.

When a participant took the supplement, the researchers noted an increase in dilation of the arteries, popliteal flow-mediated dilation, antioxidant superoxide dismutase, maximal walking time and distance, and time to claudication or leg pain.

“The results of this study reveal for the first time that acute oral intake of a mitochondrial-targeted antioxidant is effective for improving vascular endothelial function and superoxide dismutase in patients with peripheral artery disease (PAD),” Park said. “This improvement is clinically important and such antioxidants may potentially be utilized as therapeutic supplement for patients with PAD”.

The novel antioxidant, commercially available as MitoQ, contains the naturally occurring ubiquinol which is a coenzyme that gives the antixoxidant the ability to cross the cell membrane and accumulate within the mitrochondria.

Peripheral artery disease (PAD) is a common cardiovascular disease in which atherosclerotic plaque forms in the arteries of the leg which can cause decrease blood flow and reduced perfusion in the lower extremity. The disease affects nearly 200 million people worldwide, with over 20 percent of individuals over 80 years old being affected by this disease. Common symptoms often include foot ulcers and leg pain during walking. If severe, medical treatment up to and including leg amputation may be required.

This study was funded in part by the University of Nebraska at Omaha Graduate Research and Creative Activity (GRACA) grant awarded to Jiwon Song, University of Nebraska at Omaha University Committee on Research and Creative Activity (UCRCA) awarded to Song-Young Park and the NASA Nebraska Space Grant (#NNX15AI09H) awarded to Song-Young Park. Doses of MitoQ were donated to UNO by MitoQ Limited for use in this research study.

Medical benefits

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy